Combining Behavioral Treatment With Agonist Maintenance - 1

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2008 by National Institute on Drug Abuse (NIDA).
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Yale University
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000311
First received: September 20, 1999
Last updated: October 27, 2008
Last verified: October 2008
  Purpose
The purpose of this study is to evaluate whether the community reinforcement approach (CRA) plus contingency management (CM) is more effective overall than CRA only in reducing illicit opioid and cocaine use during agonist maintenance treatment and at 3 and 6 month follow-up after completion of study protocol, and to compare the efficacy of maintenance on buprenorphine to methadone when maintenance is combined with CRA only or CRA plus CM.

Condition Intervention Phase
Cocaine-Related Disorders
Opioid-Related Disorders
Substance-Related Disorders
Drug: Buprenorphine
Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Combining Behavioral Treatment With Agonist Maintenance

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Depression
  • Withdrawal symptoms
  • Opioid and cocaine use
  • Social and psychological functioning
  • AIDS risk behavior

Estimated Enrollment: 168
Study Start Date: September 1999
Arms Assigned Interventions
Experimental: 1
Therapeutic Contracting (TC)
Drug: Buprenorphine
  1. Experimental Therapeutic Contracting (TC)
  2. Experimental Cognitive Behavioral Coping Skills Therapy (CBT)
Experimental: 2
Cognitive Behavioral Coping Skills Therapy (CBT)
Drug: Buprenorphine
  1. Experimental Therapeutic Contracting (TC)
  2. Experimental Cognitive Behavioral Coping Skills Therapy (CBT)

  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000311

Locations
United States, Connecticut
APT Residential Services Division
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Yale University
Investigators
Principal Investigator: Richard Schottenfeld, M.D. Yale University
  More Information

Responsible Party: Richard S. Schottenfeld, MD, Yale University School of Medicine
ClinicalTrials.gov Identifier: NCT00000311     History of Changes
Other Study ID Numbers: NIDA-09413-1  R01-09413-1 
Study First Received: September 20, 1999
Last Updated: October 27, 2008
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Disease
Substance-Related Disorders
Cocaine-Related Disorders
Opioid-Related Disorders
Pathologic Processes
Chemically-Induced Disorders
Mental Disorders
Buprenorphine
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists

ClinicalTrials.gov processed this record on July 24, 2016